Synapse - Adult Leukemia

Results (3720)

Five-year overall survival analysis using first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase in a prospective observational study (SIMPLICITY)

Meeting Abstract

Mauro, M.; Paquette, R.; Hehlmann, R.; Williams, L. A.; Goldberg, S. L.; Michallet, M.; Gambacorti-Passerini, C.; Tang, D.; DeGutis, I. S.; McBride, A.; more...
Blood (2022)

Fulltext@MSK | Save

Pelabresib (CPI-0610) as add-on to ruxolitinib in myelofibrosis: Durability of response and safety beyond week 24 in the phase 2 MANIFEST study

Meeting Abstract

Harrison, C.; Kremyanskaya, M.; Bose, P.; Gupta, V.; Rampal, R. K.; Lambert, J.; Talpaz, M.; Vannucchi, A.; Kuykendall, A.; Kiladjian, J. J.; more...
Blood (2022)

Fulltext@MSK | Save

A risk model for CML patients with COVID-19: Importance of molecular response in the context of age, comorbidities and country income

Meeting Abstract

Radich, J. P.; Kok, C. H.; Chelysheva, E. Y.; Cortes, J. E.; Jiang, Q.; Mauro, M.; Milojkovic, D.; Moiraghi, B.; Nicolini, F. E.; Ongondi, M.; more...
Blood (2022)

Fulltext@MSK | Save

Enitociclib (VIP152/formerly BAY1251152) is a selective and active CDK9 inhibitor : Preliminary safety and early signs of efficacy in patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL)

Meeting Abstract

Shadman, M.; Mato, A. R.; Batlevi, C. L.; Flinn, I. W.; Gutierrez, M.; Uemura, M.; Stevens, D. A.; Morillo, D.; Byrd, J. C.; Frigault, M. M.; more...
Blood (2022)

Fulltext@MSK | Save

Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed / refractory mantle cell lymphoma: Additional patients and extended follow-up from the phase 1/2 BRUIN study

Meeting Abstract

Wang, M. L.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Eyre, T. A.; Cheah, C. Y.; Ujjani, C. S.; Koh, Y.; Izutsu, K.; Gerson, J. N.; more...
Blood (2022)

Fulltext@MSK | Save

Whole genome sequencing comparison of acute myeloid leukemia at presentation and remission predicts patient outcome

Meeting Abstract

Moffitt, A. B.; Alexander, J.; Stepansky, A.; Famulare, C.; Lopez, C. A.; Hakim, N.; Wu, V.; Wang, Z.; Kolitz, J. E.; Chiorazzi, N.; more...
Blood (2022)

Fulltext@MSK | Save

Erythroid and megakaryocytic differentiation program in JAK2-mutated acute myeloid leukemia with or without antecedent myeloproliferative neoplasm

Meeting Abstract

Liu, Y.; Sethi, S.; Koche, R.; Gao, Q.; Dilip, D.; Glass, J. L.; Galera, P. K.; Persaud, S.; Mishra, T.; Sun, X.; more...
Blood (2022)

Fulltext@MSK | Save

A Phase 1b dose escalation and expansion study of SNDX-5613, azacitidine (AZA) and venetoclax (VEN) in newly diagnosed, patients ≥ 60 years with untreated NPM1-mutated/ FLT3-wild type AML or KMT2A-rearranged acute myeloid leukemia (AML)

Meeting Abstract

Zeidner, J. F.; Foster, M. C.; Johnson, M.; Huang, Y.; Swords, R. T.; Stein, E.; Foran, J. M.; Baer, M. R.; Stock, W.; Madanat, Y. F.; more...
Blood (2022)

Fulltext@MSK | Save

Quantitative cytogenetic analysis with karyoParser allows for more precise identification of disease biology, clonal evolution, and etiology of relapse in acute myeloid leukemia

Meeting Abstract

Dilip, D.; Derkach, A.; Menghrajani, K.; Goldberg, A. D.; May, H.; Klimek, V. M.; Galera, P. K.; Xiao, W.; Zhang, Y.; Elemento, O.; more...
Blood (2022)

Fulltext@MSK | Save

A phase II clinical trial of E7820 for patients with relapsed/refractory myeloid malignancies with mutations in splicing factor genes

Meeting Abstract

Bewersdorf, J. P.; Stahl, M. F.; Taylor, J.; Chandhok, N. S.; Watts, J.; Derkach, A.; Wysocki, M.; Kostantakis, V.; Lu, S. X.; Bourcier, J.; more...
Blood (2022)

Fulltext@MSK | Save